Healthcare
Jagsonpal Pharmaceuticals Limited Acquires Wellness Portfolio of Group Pharmaceuticals
Jagsonpal Pharmaceuticals Ltd. acquires Wellness Portfolio of Group Pharmaceuticals, enhancing its pharmaceutical portfolio and market reach.
Jagsonpal Pharmaceuticals Limited (Jagsonpal) today announced the execution of a Business Transfer Agreement (BTA) with Group Pharmaceuticals Limited (Group Pharma) for the acquisition of its Wellness Portfolio on a going-concern basis by way of slump sale. The transaction involves an initial consideration of ₹23.7 crores on closing. Additional consideration linked to FY 2027-28 sales of up to ₹23.0 Crores, subject to a total consideration cap of ₹46.7 Crores. The transaction is expected to be completed on or before 01 November, 2026, subject to fulfilment of conditions precedent and other terms stipulated under the BTA.
Strategic Growth Move
This acquisition marks another meaningful step in Jagsonpal’s growth journey. It strengthens the company’s pharmaceutical portfolio and expands its presence across complementary therapeutic segments, especially in women healthcare, while remaining consistent with its asset-light and focused approach to growth. Commenting on the acquisition, Manish Gupta, Managing Director, Jagsonpal stated: ‘The acquisition marks another meaningful step in our growth journey. It strengthens our pharmaceutical portfolio and expands our presence across complementary therapeutic segments especially in women healthcare, while remaining consistent with our asset-light and focused approach to growth. We remain focused on pursuing opportunities that complement our existing capabilities and create sustainable, long-term value for all our stakeholders.’
Seamless Integration
Amrut Medhekar, Chief Operating Officer, Jagsonpal stated: ‘We are delighted to welcome this portfolio and the employees of the business into our organization, and are fully committed to ensuring their smooth and seamless integration. We are equally excited about this acquisition as we embark on our next phase of growth, expanding our field force, strengthening our pan-India presence and creating significant cross-selling opportunities across our portfolio. Together, we look forward to a seamless transition and unlocking the portfolio’s full growth potential by leveraging our established commercial infrastructure and strong execution capabilities.’
The transaction is subject to the fulfilment of applicable conditions precedent and other customary closing conditions as set out in the BTA. Think Law Advisors represented Jagsonpal as their legal Advisors while Tatva Legal advised Group Pharma on the transaction.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Jagsonpal posts a 0.9% three-month gain, but softens in the last few weeks. The PEG of 1.95 limits the upside. The stock does not come cheap. Revenue grows at 6.7% and profits at 17.3% CAGR. The numbers are respectable but unlikely to re-rate the stock. The stock gives back 3.4% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The stock rises 0.9% in three months on 6.7% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Jagsonpal Pharmaceuticals Limited.
Health Information Services
Indegene Limited (indgn): from Promise to Performance: Life Sciences Leaders Focus on Operationalizing AI
Indegene Limited (INDGN) highlights at Digital Summit 2026: Leaders focus on operationalizing AI for enterprise outcomes.
Indegene Limited (INDGN) recently hosted its eighth edition of the Digital Summit, focusing on operationalizing AI to deliver enterprise outcomes in the life sciences sector. The event, held on September 22 at the National Constitution Center in Philadelphia, brought together over 200 senior leaders to discuss translating AI investments into measurable business impact.
Operationalizing AI for Business Impact
The summit’s theme, ‘From Promise to Performance: Operationalizing AI for Enterprise Outcomes,’ emphasized the need for a next-generation operating model in life sciences. Speakers highlighted how AI can connect data, intelligence, and evidence to enable strategic decisions, drive successful product launches, and accelerate drug discovery and clinical research.
Recognition at VITAL Awards
The summit also hosted the second edition of the VITAL Awards, recognizing leaders delivering measurable industry impact. Honorees were named in Organizational Impact and Market Impact categories, alongside special awards for Transformational Leadership. Notable recipients included Brian Cantwell and Agam Upadhyay for Transformational Leadership, and Saket Malhotra for Organizational Impact.
Manish Gupta, Chairman and CEO of Indegene, remarked, ‘Life sciences has built an extraordinary legacy of helping people live longer, healthier lives. But increasingly specialized therapies and precision medicines cannot be supported by operating models designed for an era of mass promotion. The opportunity now is to thoughtfully rewire the enterprise around AI, augment our people, and build systems that are smarter, faster, and more responsive, turning the promise of technology into measurable performance for patients, physicians, and the business.’
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Indegene Limited
Indegene Limited belongs to the Healthcare › Health Information Services sector. Here’s a quick read on where the business and the stock stand today.
Indegene gains 15.5% over three months and trades near its 52-week highs. The PEG of 2.45 makes it expensive versus peers. The premium needs earnings to catch up quickly. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Buyers show up with 2.1x the volume of sellers. Moreover, they dominated on 15 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The stock rises 15.5% in three months on 15.0% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Indegene Limited.
GLENMARK
Glenmark Pharmaceuticals Limited Receives E Stablishment Inspection Report from U.S. FDA
Glenmark Pharmaceuticals Limited (GLENMARK) receives Establishment Inspection Report from U.S. FDA for its Goa facility with Voluntary Action Indicated status.
Glenmark Pharmaceuticals Limited (GLENMARK) announced today that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its formulations manufacturing facility in Goa, India, with a Voluntary Action Indicated (VAI) status. The inspection was conducted from June 22, 2026, to June 30, 2026. This report is a significant milestone for the company as it underscores the quality and compliance of its manufacturing processes.
Inspection Highlights
The U.S. FDA’s inspection team evaluated various aspects of the manufacturing facility, including production protocols, quality control measures, and overall facility management. Notably, the FDA highlighted areas that require voluntary actions to address certain observations. This VAI classification indicates that while the facility meets most regulatory standards, there are specific areas needing improvement.
Company’s Response
Glenmark Pharmaceuticals Limited is committed to addressing the observations mentioned in the report. The company plans to implement corrective and preventive actions to ensure full compliance with FDA standards. This proactive approach will help Glenmark maintain its reputation for high-quality pharmaceutical manufacturing.
As a result, Glenmark Pharmaceuticals Limited continues to focus on innovation and accessibility, aiming to deliver affordable and high-quality medicines globally. The company’s robust manufacturing infrastructure and commitment to excellence will drive its ongoing success and compliance with international regulatory standards.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Glenmark rises 12.9% over three months, with buying pressure holding steady. The PEG of 0.59 signals undervaluation relative to growth. It is a potential re-rating candidate. Revenue grows at 13.5% and profits at 66.1% CAGR. The market consistently rewards this kind of compounding. The stock trades at 90% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 13.5%, profits at 66.1%, and the PEG sits at 0.59 — below its growth rate. That combination is rare. Check Fundamentals of Glenmark Pharmaceuticals Limited.
Healthcare
Hikal Limited (hikal) Ventures into Personal Care: New CGMP Panoli Facility Begins Commercial Production
Hikal Limited (HIKAL) announced the commercial production of its Personal Care products from its new cGMP-compliant facility in Panoli, marking its entry int.
Hikal Limited (HIKAL) has marked a significant milestone with the successful commercial production of its Personal Care products from its new cGMP-compliant, multipurpose manufacturing facility in Panoli, Gujarat. This new facility represents Hikal’s formal entry into the commercial-scale supply for the global beauty and personal care industry, aligning with the company’s broader strategy of building new, high-value growth platforms alongside its established Pharmaceuticals, Crop Protection, and Animal Healthcare businesses.
Strategic Entry into Personal Care
As part of its strategic commitment to this new segment, Hikal repurposed an existing manufacturing asset at Panoli to serve the evolving needs of the global beauty and personal care industry. The facility has recently commenced commercial production and successfully manufactured its first production batches. Product samples have been validated with customers, and the company has received encouraging feedback, resulting in a positive market pull for its product portfolio.
Focus on Beauty & Personal Care
Hikal’s initial focus within Personal Care is on the Beauty & Personal Care segment, particularly the skin care category, where demand continues to grow globally. The company has built a strong portfolio of second-generation UV filters, offering enhanced performance and closer alignment with evolving consumer preferences and tightening regulatory requirements across key markets. These products are undergoing approvals by its global customers, as part of Hikal’s continued strategy of portfolio diversification beyond its core Pharma and Crop Protection segments.
“Personal Care represents the kind of long-term opportunity we look for. We’ve applied the same disciplined approach that built our Pharmaceuticals and Crop Protection businesses, deep customer partnerships, rigorous quality systems, and patient capital investment, to a new category where global demand for specialty skincare ingredients is accelerating. Commissioning the Panoli facility, manufacturing our first production batches, and securing positive customer feedback points towards the growth of the business in the coming years,” said Sameer Hiremath, Vice Chairman & Managing Director, Hikal Limited.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Hikal Limited
Hikal Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Hikal holds in the upper half of its 52-week range, a sign the market backs the stock. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 4 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock holds at 61% of its 52-week range with RSI at 53. In other words, neither side has a clear edge right now. Price climbs recently despite -5.4% revenue growth and a PEG of 99.00. Consequently, either institutions position ahead of improvement or the move fades when earnings disappoint. Treat this as a trading signal, not an investment thesis. Check Fundamentals of Hikal Limited.
-
DBL2 days agoDilip Buildcon Limited (DBL) Sells Stake in Under-construction Solar Portfolio to Alpha Alternatives
-
Apparel Manufacturing2 days agoIris Clothings Limited (irisdoreme) Expands Doreme’s Digital Footprint Through Amazon Partnership
-
PREMIERENE2 days agoPremier Energies Limited (premierene) Commissions India’s Largest Solar Cell Facility
-
Information Technology Services2 days agoMagellanic Cloud Limited (NSE: Mcloud) Enters AI Smart Fuel Infrastructure Market with Nayara Energy Contract
-
Information Technology Services2 days agoPersistent Systems Limited (persistent) Earns Databricks Brickbuilder Specialization for BFSI
-
Industrials2 days agoTransrail Lighting Limited (NSE: Transraill) Increases Conductor Manufacturing Capacity by 70%
-
Energy2 days agoOil & Natural Gas Corporation Limited (ongc) Discovers Gas Flow in Deepwater Exploration
-
BIOCON2 days agoBiocon Limited (biocon) Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval